# First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Source: https://onco.cc/trials/nct06603844/  
OnCo record `nct06603844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CRB-601 monoclonal antibody in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.

## Summary

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT06603844 by Corbus Pharmaceuticals Inc., with 156 participants planned, started 2024-12-04 and due to reach its primary completion in 2026-11-01. Interventions recorded: CRB-601 monoclonal antibody and Anti-PD-1 monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06603844
- Phase: 1/2
- Setting: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors
- Sponsor: Corbus Pharmaceuticals Inc.
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT06603844: https://clinicaltrials.gov/study/NCT06603844

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Corbus Pharmaceuticals](https://onco.cc/companies/corbus-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06603844.json